Answer
Ritonavir inhibits CYP3A, while Flutiform's fluticasone propionate is a CYP3A4 substrate, increasing systemic corticosteroid side-effect risk; this combination should be avoided unless benefits outweigh that increased risk, in which case patients should be monitored for these effects.
Sources for this answer
- flutiform 50 microgram/5 microgram, 125 microgram/5 microgram and 250 microgram/10 microgram per actuation pressurised inhalation, suspensionNapp Pharmaceuticals Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked